scholarly journals Life events and quality of life in patients of Cushing's disease

2019 ◽  
Vol 3 (1) ◽  
pp. 28
Author(s):  
Neena Sawant ◽  
Akanksha Sharma ◽  
Nalini Shah
Keyword(s):  
Quality Of Life ◽  
Life Events ◽  
Cushing’S Disease ◽  
Cushing's Disease

The development of the Tuebingen Cushing’s disease quality of life inventory (Tuebingen CD-25). Part II: normative data from 1784 healthy people

2012 ◽  
Vol 76 (6) ◽  
pp. 861-867 ◽  
Author(s):  
Monika Milian ◽  
Philipp Teufel ◽  
Juergen Honegger ◽  
Baptist Gallwitz ◽  
Guenter Schnauder ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cushing’S Disease ◽  
Normative Data ◽  
Healthy People ◽  
Cushing's Disease ◽  
Quality Of Life Inventory ◽  
Life Inventory

scholarly journals Bilateral adrenalectomy in Cushing's disease: Altered long-term quality of life compared to other treatment options

2019 ◽  
Vol 80 (1) ◽  
pp. 32-37 ◽  
Author(s):  
Pauline Sarkis ◽  
Muriel Rabilloud ◽  
Jean-Christophe Lifante ◽  
Anna Siamand ◽  
Emmanuel Jouanneau ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cushing’S Disease ◽  
Treatment Options ◽  
Bilateral Adrenalectomy ◽  
Cushing's Disease

scholarly journals Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease

2014 ◽  
Vol 171 (1) ◽  
pp. 89-98 ◽  
Author(s):  
Susan M Webb ◽  
John E Ware ◽  
Anna Forsythe ◽  
Min Yang ◽  
Xavier Badia ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cushing’S Disease ◽  
Treatment Effectiveness ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Cushing's Disease ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

ObjectiveCushing's disease (CD) can significantly impair patients' health-related quality of life (HRQOL). This study investigated the treatment effectiveness of pasireotide on HRQOL of CD patients, and assessed the relationships between HRQOL and urinary free cortisol (UFC) and CD-related signs and symptoms.DesignIn this phase III, randomized, double-blind study, patients with UFC ≥1.5×upper limit of normal (ULN) received s.c. pasireotide 600 or 900 μg twice daily. The trial primary endpoint was UFC at or below ULN at month 6 without dose titration. Open-label treatment continued through month 12. HRQOL was measured using the Cushing's Quality of Life Questionnaire (CushingQoL) instrument at baseline and follow-up visits until month 12 during which clinical signs and features of CD, and the Beck Depression Inventory II (BDI-II), were also collected.MethodsPearson's/Spearman's correlations between changes in CushingQoL and changes in clinical signs and symptoms were assessed. Changes in CushingQoL and the proportion of patients achieving a clinically meaningful improvement in CushingQoL were also compared among patients stratified by mean UFC (mUFC) control status (controlled, partially controlled, and uncontrolled) at month 6. Analyses were also conducted at month 12, with multivariable adjustment for baseline characteristics and CushingQoL.ResultsChange in CushingQoL was significantly correlated with changes in mUFC (r=−0.40), BMI (r=−0.39), weight (r=−0.41), and BDI-II (r=−0.54) at month 12 but not at month 6. The percentage of CushingQoL responders at month 12 based on month 6 mUFC control status were as follows: 63, 58.8, and 37.9% in the controlled, partially controlled, and uncontrolled groups respectively. Adjusted CushingQoL scores at month 12 were 58.3 for controlled patients (Δ=11.5 vs uncontrolled,P=0.012) and 54.5 for partially controlled patients (Δ=7.7 vs uncontrolled,P=0.170).ConclusionsPasireotide treatment can result in a meaningful HRQOL improvement among those who complete a 12-month treatment period, most often among patients achieving biochemical control.

Tuebingen CD-25 Is a Sensitive Tool to Investigate Health-Related Quality of Life in Cushing's Disease Patients in the Course of the Disease

2013 ◽  
Vol 98 (3) ◽  
pp. 188-199 ◽  
Author(s):  
Monika Milian ◽  
Juergen Honegger ◽  
Philipp Teufel ◽  
Alena Wolf ◽  
Tsambika Psaras
Keyword(s):  
Quality Of Life ◽  
Cushing’S Disease ◽  
Cushing's Disease ◽  
Health Related Quality ◽  
Sensitive Tool ◽  
Related Quality ◽  
Health Related

Predictors of quality of life in 102 patients with treated Cushing's disease

2014 ◽  
Vol 82 (3) ◽  
pp. 404-411 ◽  
Author(s):  
Alessia Carluccio ◽  
Nina K. Sundaram ◽  
Sumedha Chablani ◽  
Levana G. Amrock ◽  
Jessica K. Lambert ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cushing’S Disease ◽  
Cushing's Disease

scholarly journals MANAGEMENT OF ENDOCRINE DISEASE: The burden of Cushing's disease: clinical and health-related quality of life aspects

2012 ◽  
Vol 167 (3) ◽  
pp. 311-326 ◽  
Author(s):  
R A Feelders ◽  
S J Pulgar ◽  
A Kempel ◽  
A M Pereira
Keyword(s):  
Quality Of Life ◽  
Cushing’S Disease ◽  
Treatment Options ◽  
Current Treatment ◽  
Cushing's Disease ◽  
Health Related Quality ◽  
Time To Diagnosis ◽  
Related Quality ◽  
Health Related

ObjectiveCushing's disease (CD) is a rare endocrine disorder characterized by excess secretion of ACTH due to a pituitary adenoma. Current treatment options are limited and may pose additional risks. A literature review was conducted to assess the holistic burden of CD.DesignStudies published in English were evaluated to address questions regarding the epidemiology of CD, time to diagnosis, health-related quality of life (HRQoL), treatment outcomes, mortality, prevalence of comorbidities at diagnosis, and reversibility of comorbidities following the treatment.MethodsA two-stage literature search was performed in Medline, EMBASE, and Science Citation Index, using keywords related to the epidemiology, treatment, and outcomes of CD: i) articles published from 2000 to 2012 were identified and ii) an additional hand search (all years) was conducted on the basis of bibliography of identified articles.ResultsAt the time of diagnosis, 58–85% of patients have hypertension, 32–41% are obese, 20–47% have diabetes mellitus, 50–81% have major depression, 31–50% have osteoporosis, and 38–71% have dyslipidemia. Remission rates following transsphenoidal surgery (TSS) are high when performed by expert pituitary surgeons (rates of 65–90%), but the potential for relapse remains (rates of 5–36%). Although some complications can be partially reversed, time to reversal can take years. The HRQoL of patients with CD also remains severely compromised after remission.ConclusionsThese findings highlight the significant burden associated with CD. As current treatment options may not fully reverse the burden of chronic hypercortisolism, there is a need for both improved diagnostic tools to reduce the time to diagnosis and effective therapy, particularly a targeted medical therapy.

Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing’s disease

Pituitary ◽  
2012 ◽  
Vol 16 (4) ◽  
pp. 536-544 ◽  
Author(s):  
R. van der Pas ◽  
C. de Bruin ◽  
A. M. Pereira ◽  
J. A. Romijn ◽  
R. T. Netea-Maier ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Medical Treatment ◽  
Diurnal Rhythm ◽  
Cushing’S Disease ◽  
Cushing's Disease

Evaluation of depression, quality of life and body image in patients with Cushing’s disease

Pituitary ◽  
2012 ◽  
Vol 16 (3) ◽  
pp. 333-340 ◽  
Author(s):  
Nilufer Alcalar ◽  
Sedat Ozkan ◽  
Pinar Kadioglu ◽  
Ozlem Celik ◽  
Penbe Cagatay ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Body Image ◽  
Cushing’S Disease ◽  
Cushing's Disease
Sign in / Sign up

Export Citation Format

Share Document